Metronomic oral cyclophosphamide in patients with advanced solid tumors

Onkologie

Volumn 35, Issue 1-2, 2012, Pages 35-38

  Bojko, Peter ^a   Schimmel, Gudrun ^a   Bosse, Daniel ^a   Abenhardt, Wolfgang ^a  

^a Diagnostik München   (Germany)

Author keywords

Oral cyclophosphamide; Solid tumors

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; GONADORELIN AGONIST; STEROID; TRASTUZUMAB; ZOLEDRONIC ACID;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG TREATMENT FAILURE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATURIA; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MALE; METRONOMIC DRUG ADMINISTRATION; NAUSEA; OVERALL SURVIVAL; PAIN; PNEUMONIA; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERUS CARCINOMA;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SURVIVAL RATE; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84856889643     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000336144     Document Type: Article

References (13)

1. Foye LV JR, Chapman CG, Willett FM, Adams WS: Cyclophosphamide. A preliminary study of a new alkylating agent. Arch Intern Med 1960;106: 365-367.
2. Rozados VR, Mainetti LE, Rico MJ, Zacarias Fluck MF, Matar P, Scharovsky OG: The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol Res 2010;18:601-605.
3. Lennernäs B, Albertsson P, Lennernäs H, Norrby K: Chemotherapy and antiangiogenesis - drugspecific, dose-related effects. Acta Oncol 2003;42: 294-303. (Pubitemid 36851146)
4. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO: Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 2002;50:588-596. (Pubitemid 34045258)
5. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO: Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol 2001;1:307-319. (Pubitemid 32183729)
6. Hsu JY, Wakelee HA: Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. Bio- Drugs 2009;23:289-304.
7. Ivy SP, Wick JY, Kaufman BM: An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6:569-579.
8. Grothey A, Galanis E: Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-518.
9. Stoelting S, Trefzer T, Kisro J, Steinke A, Wagner T, Peters SO: Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 2008;22:831-836.
10. Penel N, Clisant S, Dansin E, Desauw C, Degardin M, Mortier L, Vanhuyse M, Bonodeau F, Fournier C, Cazin JL, Adenis A: Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer 2010;102:1207-1212.
11. Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, Florin V, Martinot V, Penel N, Vercambre-Darras S, Mortier L: Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 2010;28: 684-689.
12. Görn M, Habermann CR, Anige M, Thöm I, Schuch G, Andritzky B, Brandt S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C, Laack E: A pilot study of docetaxel and trofosfamide as second-line metronomic chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 2008;31:185-189. (Pubitemid 351700542)
13. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, Custodio A, Casado A, Diaz-Rubio E: Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother 2008;20:632-639.